Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing its Immuno-STAT platform to selectively modulate disease-specific T cells, aiming to restore immune balance in autoimmune, inflammatory and oncology indications.
The company’s lead autoimmune candidate, CUE-401, is a bifunctional TGF-β/IL-2 fusion protein designed to expand and induce regulatory T cells and reduce pro‑inflammatory cells. IND‑enabling work and GLP toxicology in mice and non‑human primates are nearing completion, and Cue plans to file an IND in the second quarter of 2026, with initial human safety data expected in the second half of 2026.
The CUE-500 series, including CUE-501, targets pathogenic cells such as autoreactive B cells by redirecting anti‑viral memory T cells and is licensed globally to Boehringer Ingelheim for B‑cell depletion applications. The oncology‑focused CUE-100 series, including CUE‑101 and CUE‑102, has been licensed to ImmunoScape for cell‑therapy applications in solid tumors, providing upfront and milestone economics while Cue retains non‑oncology rights for a period.
Cue operates under a core technology license from Albert Einstein College of Medicine, with royalties and up to $1.85M in milestones per product and $5.75M tied to cumulative sales, and has additional collaborations with LG Chem and ImmunoScape. The company reports recurring operating losses, no approved products, a substantial doubt about its ability to continue as a going concern, and warns it will require substantial additional financing and successful partnerships to advance its pipeline.
Cue Biopharma will hold its 2026 annual meeting of stockholders virtually on April 13, 2026 at 9:00 a.m. Eastern Time. Agenda items include the election of seven directors, ratification of RSM US LLP as auditor, a non-binding advisory vote on executive compensation and a proposed reverse stock split at a ratio between 1-for-30 and 1-for-50 with the exact ratio and timing to be determined by the board.
Stockholders of record as of the close of business on March 9, 2026 may vote online at www.virtualshareholdermeeting.com/CUE2026. Proxy materials and the 2025 Annual Report (Form 10-K) will be mailed and posted on or about March [__], 2026.
Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026. The company explains how stockholders can submit proposals or director nominations for that meeting and the deadlines that apply.
Stockholder proposals intended for inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at Cue Biopharma’s Boston headquarters by February 28, 2026, which the company considers a reasonable time before it begins printing and mailing proxy materials. For other business or director nominations to be brought directly before the meeting under the company’s Amended and Restated Bylaws, notice must also be received by February 28, 2026, or the later of 90 days before the meeting and 10 days after public announcement of the meeting date.
The company notes that stockholders who plan to solicit proxies in favor of their own director nominees, rather than the company’s nominees, and who seek to comply with the SEC’s universal proxy rule (Rule 14a-19), must likewise provide the required notice by February 28, 2026. If a stockholder misses these deadlines, the board’s named proxies may exercise discretionary voting authority on that stockholder’s proposal at the 2026 Annual Meeting.
Cue Biopharma appointed Lucinda WarrenChief Financial and Business Officer
Warren has over 30 years of global experience in pharmaceuticals and biotechnology, including a decade in business development roles at Johnson & Johnson and leadership positions at Janssen organizations. She receives no additional compensation for these new responsibilities, her employment terms remain unchanged, and there are no related-party or family relationships tied to her appointment.
Cue Biopharma director Peter A. Kiener reported a new stock option grant dated 01/02/2026. He received a stock option for 24,400 shares of Cue Biopharma common stock with an exercise price of $0.34 per share, recorded as an acquisition of derivative securities. The option was granted under the company’s Director Compensation Policy and is scheduled to become fully exercisable on the first anniversary of the grant date, with an expiration date of 01/01/2036. Following this grant, Kiener beneficially owns 24,400 stock options directly.
Cue Biopharma, Inc. reported a routine insider transaction showing a stock option grant to director Pamela Garzone. On 01/02/2026, she received 24,400 stock options with an exercise price of $0.34 per share. According to the disclosure, the award was granted under the company’s Director Compensation Policy.
The filing states that this stock option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Garzone beneficially owns 24,400 derivative securities directly, reflecting only this option award.
Cue Biopharma director Sarraf Pasha reported receiving a stock option award from the company. On 01/02/2026, Pasha was granted an option to buy 24,400 shares of Cue Biopharma common stock at an exercise price of $0.34 per share, with no cash paid for the grant itself. The award was made under the company’s Director Compensation Policy.
The filing states that this option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Pasha beneficially owns 24,400 derivative securities in the form of these stock options, held directly.
Cue Biopharma is conducting a public offering of common stock, pre‑funded warrants and common stock warrants, all sold together as units. The pre‑funded warrants have a de minimis exercise price and are exercisable on a cashless basis, while the common stock warrants are exercisable for five years and may be cashless if no effective registration is available.
The company is a clinical‑stage biopharmaceutical developer using its Immuno‑STAT platform to target disease‑specific T cells in autoimmune diseases. As of September 30, 2025, it held $18.7 million in cash, cash equivalents and marketable securities and has a collaboration providing a $5.0 million upfront payment and a further $5.0 million time‑based payment due in December 2025, which together are expected to fund operations into the third quarter of 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern and that proceeds from this offering will not be sufficient to remove that doubt, and notes that additional equity financing is likely to be dilutive.
Cue Biopharma, Inc. (CUE) reported a Form 4 transaction for its Chief Business Officer. The officer received a stock option grant covering 125,000 shares of Cue Biopharma common stock on 09/29/2025. The option has an exercise price of $0.72 per share and expires on 09/28/2035.
According to the filing, this stock option becomes fully exercisable on the first anniversary of the grant date, meaning the officer must wait one year before the option is fully vested. Following this grant, the officer beneficially owns 125,000 derivative securities, held directly. This transaction reflects equity-based compensation designed to align the officer’s interests with those of shareholders.
Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.